Revvity The Alphalisa® Immunoassay Kit For Human

Formats:

Our 100 assay point kit allows you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample). Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample). Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

AlphaLISA features:

No-wash steps, no separation steps ELISA alternative technology Sensitive detection Broad sample compatibility Small sample volume Results in less than 3 hours Half the time of an ELISA assay

AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

IL-18BP, also known as IL18 BPa, IL-18 BPa, IL18BP, IL18BPa, and interleukin 18 binding protein, is a 20 kDa protein constitutively expressed and secreted from mononuclear cells. IL-18BPa contains one immunoglobulin (Ig)-like C2-type domain that has been shown to be essential to the binding and neutralizing properties of the binding protein. IL18BP is known as an inhibitor of the proinflammatory cytokine, IL-18. The production and secretion of IL-18BP is stimulated by IFNγ. IL-18BP binds to IL-18 to prevent the binding of IL-18 to its receptor and to inhibit IL-18-induced IFNγ production, resulting in reduced TH1 immune responses. An elevated level of this protein is detected in the intestinal tissues of patients with Crohns disease, hematological malignancies, inflammatory diseases, and autoimmune disorders.